Corcept stock drops after drugmaker loses patent lawsuit against Teva
Corcept Therapeutics Inc. shares (CORT) dropped 32% premarket on Tuesday after a federal court in New Jersey on Friday ruled against the drugmaker in its patent infringement lawsuit against Teva Pharmaceutical Industries Ltd. (TEVA). Teva seeks to market a generic version of Corcept's Korlym, a treatment for the endocrine disorder Cushing's syndrome, but Corcept failed to demonstrate that there is a likely direct infringement of its patent claims for the drug, the court said in its opinion. "This disappointing decision is based on legal and factual errors we are confident will be reversed on appeal," Corcept CEO Dr. Joseph Belanoff said in a statement Tuesday. "We will pursue our appeal vigorously," Belanoff said, "and will continue to assert our intellectual property rights whenever they are infringed." Teva did not immediately respond to a request for comment. Corcept shares gained about 60% in 2023. Teva's American depositary receipts fell 0.1% premarket on Tuesday and gained 14.5% over the past 12 months.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-02-24 0818ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks